Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

“Since its commercial launch in the United States, Omnipod 5 has had a remarkable impact on people with diabetes,” said Jim Hollingshead, Insulet President and CEO. “Every day, we hear how this ...

Insulet stock rose moderately early Thursday as its insulin pump, Omnipod, delivered double-digit growth in the U.S. and ...

Insulet’s recent earnings call paints a picture of robust performance and strategic growth, marked by record revenue achievements and significant market expansion. The sentiment was overwhelmingly ...

Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...

Mar. 18, 2025 6:05 AM ETInsulet Corporation (PODD) “Bringing our life-changing flagship Omnipod 5 to people living with diabetes in these four new countries is both incredibly exciting and meaningful, ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...

The user-friendly Omnipod has been particularly successful among children and teens. After a major management changeover in 2014-15, Insulet has improved its manufacturing and commercialization ...

Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Diabetes management software company Glooko will add its first two continuous glucose monitor and pump integrations into its offering: Dexcom's G4 CGM and Insulet's OmniPod Insulin Management System.